SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quarter fiscal 2025 ended June 30, 2025. “A strong balance sheet and disciplined cost-management underpin our focused business execution,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. Visit the Events and Presentations page of the Investor Relations section under the “Company” ta
Related Questions
Did the company announce any capital‑expenditure plans, facility expansions, or technology investments that could impact cash flow?
How does the company’s profit margin and operating expense trends compare to its peers in the synthetic DNA and biotechnology space?
What guidance did the company provide for FY2025 and FY2026 revenue, earnings, and cash flow?
What are the key drivers behind the reported financial results (e.g., product mix, pricing, volume, or cost‑management initiatives)?
Are there any risks or uncertainties highlighted in the release (e.g., supply‑chain constraints, regulatory changes, or competitive pressures) that could impact the stock?
How did Twist Bioscience's Q3 2025 revenue and earnings compare to the previous quarter and year‑over‑year?
How did the company's guidance and outlook affect analyst sentiment and target price revisions?
What is the current cash position and debt level, and how does it affect the company’s financial flexibility?
What is the implied valuation impact of this earnings release on the stock’s price‑to‑sales, price‑to‑earnings, and other valuation multiples?
What new customers, partnerships, or product launches were announced during the quarter, and how might they affect future growth?